‘Breakthrough’ mRNA cancer vaccine cuts melanoma recurrence in major trial
US drugmakers Merck and Moderna said Wednesday that a personalised cancer treatment significantly reduced the risk of melanoma recurrence in a late-stage clinical trial, with experts hailing the results as a potential “breakthrough”.
The…
Read More...
Read More...